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ABSTRACT  
Background People with severe mental illness (SMI) generally have high rates of metabolic syndrome (MetS). 
Proposed explanations remain conjectural. Relatively little is known about Mets in SMI in Southern Europe, an area 
with generally healthy dietary traditions. 
Purpose To establish prevalence rates of MetS in an Italian sample, testing hypotheses about putative reasons for the 
excess in the SMI group. 
Methods We compared the prevalence and correlates of MetS in inpatients with SMI and controls randomly chosen 
from patients undergoing routine maxillofacial surgery. We employed formal tests of mediation. 
Results The MetS prevalence rate was 26.1% in the SMI group and 15.9% in the comparison group. After controlling 
for age, people with SMI were three times more likely to have MetS than their non-SMI counterparts. Smoking and a 
family history of cardiovascular disease were strongly related to MetS in both groups. However, these factors could not 
explain the excess of MetS in the SMI group, and we found no effect of antipsychotic dose. 
Conclusions SMI remained prominent in increasing the likelihood of MetS in this low prevalence population, and 
putative determinants of MetS were common to people with SMI and to controls. Explanations for high MetS rates in 
SMI may lie in health behaviours other than smoking.  
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INTRODUCTION  
People suffering from severe mental illness (SMI) have a shorter life expectancy than the general population [1]. 
Suicide and accidental injury account for 30-40% of this excess mortality [2], while cardiovascular disease (CVD) 
causes the vast majority of deaths from physical illness [3]. The increased frequency of CVDs in SMI is likely to 
involve a number of risk factors commonly considered modifiable in the general population. These include smoking, 
poor diet, lack of exercise, excessive alcohol intake, obesity, diabetes, and dyslipidaemia [4]. The cluster of abnormal 
clinical and metabolic findings defining the metabolic syndrome (MetS) is predictive of CVDs [5], and may be of 
particular importance in SMI. The most frequently used definition of MetS is that set out by the Adult Treatment Panel 
ATP-III of the US National Cholesterol Education Program (NCEP), [6].  
The large Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study applied the NCEP definition of 
MetS to people with chronic schizophrenia. The odds of having MetS were two and three times greater respectively in 
men and women with schizophrenia than the age-adjusted prevalence rate of 23.7% in American adults [7]. However, 
the prevalence rates of MetS in people with SMI actually vary strikingly in different geographic locations, ranging from 
3.9% to 54% [8]. Some of this variation may result from sampling biases in relation to sociodemographic and clinical 
characteristics. Nevertheless, local social characteristics and dietary habits may also have an important bearing. 
Understanding the inconsistencies in the prevalence of MetS in people with SMI should reveal the impact of local social 
circumstances, and whether variations are just as apparent as in the general population. Moreover, good prevalence data 
are crucial in terms of the financial resources to be allocated, and the training needed for planning basic primary 
prevention and routine diagnostic screening for MetS and CVD risk factors in this vulnerable group. Finally, the 
variation may have aetiological implications.  
Three key candidates for explaining the association are predisposition due to genetic overlap between SMI and MetS, 
antipsychotic medication, and detrimental health behaviours. Certainly, a genetic association between SMI and MetS 
cannot be ruled out [9]. Antipsychotic medication has been associated with an increased prevalence of MetS: there is a 
dose effect for CVD risk factors and some agents seem to have an especially adverse impact [10]. The fact that over a 
third of people with established schizophrenia taking antipsychotic medication can, by the age of 38, be identified 
biochemically to be at high risk of diabetes emphasises the importance of prevention [11]. Finally, people with SMI are 
particularly likely to smoke, to have a poor diet, and to avoid exercise, and this may be linked to deficiencies in relevant 
skills, self-efficacy and motivation [12]. Each of these aetiological possibilities may be illuminated by studying them in 
geographical contexts with particular attributes.  
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The population of countries in Southern Europe usually show reduced CVD-related mortality rates, possibly because of 
healthy Mediterranean dietary habits [13]. This region thus offers opportunities for studying the prevalence of MetS in 
relation to family history, to antipsychotic medication and to adverse health behaviours in people with SMI. If these are 
important causes of MetS, the relative odds of MetS in people with SMI should be relatively increased in the context of 
healthy eating habits at the population level. However, previous epidemiological studies in Southern Europe have been 
hampered by methodological issues. Samples have often been based on clinical convenience [14], and control groups 
have been unsuitable for a number of reasons, lacking relevant healthy comparison groups [15], using comparison 
samples from different populations [16] or based on large existing administrative databases [17].  
 
Aims of the study 
The present study was designed to examine the prevalence of MetS in a representative cohort of people with SMI in 
Italy. We hypothesised, i) that, after adjusting for relevant clinical and social variables, people with SMI would have 
higher MetS rates than those free of mental disorder, and ii) that the association between SMI and MetS would be 
mediated by a family history of CVD, the level of antipsychotic medication, and smoking habits.  
 
MATERIALS AND METHODS 
Setting and study design  
The study took place in Monza-Brianza (MB), a mixed urban and rural province in Northern Italy, which includes 
districts ranging from the most to the least deprived in Italy. It was approved by the local research ethics committee 
(code “Non solo mente”). 
The study was a cross-sectional comparison of people with and without SMI, recruited from patients admitted to San 
Gerardo University Hospital (MB). This eleven hundred bed general hospital has a comprehensive range of medical and 
surgical inpatient services, and a 20 bed ward for acute mental health care serving a catchment area of 319,000 
inhabitants. 
Sample 
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All patients with a DSM-IV diagnosis of SMI admitted to the Mental Health Inpatient Unit between March 2011 and 
February 2012 were approached for informed, signed, consent to the study. If they agreed, they were interviewed on the 
day before their planned discharge in order to check their diagnosis. SMI was defined as at least one 12-month DSM-
IV/SCID diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief 
psychotic disorder, shared psychotic disorder, psychotic disorder NOS, and bipolar I–II disorders, together with a GAF 
score of less than 60 for at least one month in the past year [18]. In the same period, all inpatients from the maxillofacial 
surgery unit admitted for planned, routine (non-emergency) surgical treatment were approached in order to establish an 
eligible list for the general hospital comparison group. We chose this clinical population as unlikely to suffer more from 
chronic physical disorders than the general population. To be eligible, people from both groups had to be at least 18 
years old and living in a private residence. People were excluded from the comparison group if they had received a 
formal SMI diagnosis, had ever taken an antipsychotic medication, or were on the caseload of a mental health service.  
Procedure 
Fully trained consultant psychiatrists administered the 12-month patient version of the SCID-I [Structured Clinical 
Interview for DSM-IV] [19] to identify SMI diagnoses within the index group.  
Definition of the metabolic syndrome 
MetS was defined by the presence of three or more of the following criteria [12]: 
 abdominal obesity (waist circumference > 102cm in men and > 88cm in women) 
 fasting triglycerides concentration ≥ 150 mg/dl 
 systolic/diastolic blood pressure ≥ 130/85 mmHg (or on antihypertensive medication) 
 high density lipoprotein (HDL) cholesterol < 40 mg/dl in men and < 50 mg/dl in women 
 fasting glucose concentration ≥ 110 mg/dl (or on insulin or hypoglycaemic medication). 
Where it was infeasible to measure waist circumference (i.e., for a small proportion of bedridden patients) we 
substituted an abdominal obesity criterion equivalent to a body mass index (BMI) value ≥ 28.8 kg/m2, without losing 
reliability [20].  
Data collection  
General socio-demographic information (age, gender, education, employment status, family situation) was collected. 
We elicited clinical data covering current medication for hypertension, dyslipidaemia and diabetes, clinical and family 
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history of CVDs (e.g., myocardial infarction, acute heart failure, acute coronary syndrome, and stroke), and self-
reported smoking habits. Participants with SMI were asked about current antipsychotic medication, and the information 
cross-checked in clinical records. The amounts prescribed in the past six months were converted to average 
chlorpromazine equivalent doses [21-24]. The routine admission procedure established height and weight (on electronic 
scales, with the minimal necessary clothing), and BMI. Waist circumference was measured according to standard 
guidelines [25]. Resting blood pressure was established at the beginning and end of the interview, and the mean value 
was determined. Fasting plasma levels of glucose, triglycerides and total cholesterol (LDL plus HDL) were measured. 
Statistical analysis 
Our sample size calculation was based on an Italian national prevalence for MetS of 20% [26] and meta-analytic data 
suggesting MetS rates of 40% in people with SMI [27]. Groups of 119 participants would allow the demonstration of a 
20% differences in MetS rates, given 90% power and a two sided 5% level of significance, as previously reported [7]. 
In total, 208 and 196 individuals were eligible for the SMI and comparison groups respectively. We used simple 
random sampling to obtain the requisite number of subjects from the enrolled populations. The sample size calculation 
was also appropriate for the chosen tests for mediation, even though these have less statistical power. 
Analyses were carried out using Stata for Windows version 10.0 SE. We used logistic regression in a structured 
approach to analyse the effect of SMI on the prevalence of MetS. We controlled for age and sex, and then added the 
variables we had identified as putative explanations for the increased rate of MetS in people with SMI, using Sobel-
Goodman tests for mediation as framed in the sgmediation command in Stata. We used mediation analyses to test 
whether the relationship between SMI (independent variable) and MetS (dependent variable) is direct or whether 
putative mediator variables account for the relationship between them. Our data allowed us to consider three candidate 
mediators. The first possibility is that there is an overlap between the genes associated with MetS and SMI. We used a 
family history (FH) of CVD as a partial proxy for the genetic basis of MetS. If there is genetic overlap, this would be 
expressed as mediation of the SMI-MetS link by FH CVD. The second possibility is that treatment with antipsychotic 
drugs increases the risk of MetS. If so, there should be a dosage effect, and antipsychotic dose should fulfil the 
requirements for mediation. Finally, the explanation might lie in harmful health behaviours, and we therefore examined 
the contribution of smoking status.  
Having ascertained that: 1) there is a direct effect between SMI and MetS; and 2) the putative mediator variables are 
associated with MetS, we used Sobel-Goodman tests for mediation to assess if the association between SMI and MetS is 
reduced by a significant amount (partial mediation), or is completely accounted for, by the mediator (total mediation). 
Each putative mediator was entered in separate models in order to investigate their individual impact on the 
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relationship. If the entry of the mediator was accompanied by a statistically significant effect on the dependent variable, 
together with a reduction of the SMI effect, partial mediation can be deduced (indirect effect). On the other hand, if the 
effect of the mediator lacks statistical significance, all that can be inferred is a direct effect of SMI on MetS.  
RESULTS 
No eligible patient refused to participate in the study. In table 1, people with SMI are compared with the control 
participants. The prevalence rate for ATP III metabolic syndrome in people with SMI was 26.1%, 60% higher than in 
the comparison group (15.9%). The latter is almost identical to that found (16.2%) in a large epidemiological study of 
the same geographical area [28]. This supports the representativeness of our control group, and, indirectly, our 
prevalence estimates for the SMI group. People in the SMI group were less often married or cohabiting, and fewer were 
employed. There was no difference in educational level or age. However, there was an unexpected under-representation 
of males in the SMI group, approaching conventional levels of statistical significance (p=0.07), and the excess 
prevalence of MetS in the SMI group was restricted to female participants. Rates in the SMI group were higher in 
females than in males, while the reverse was true in the control group.  
Table 1 about here 
Because of these sex differences, we analysed formally whether sex moderated the relationship between SMI and the 
metabolic syndrome (Table 2). While SMI and sex were both significantly related to MetS, an interaction term linking 
sex with SMI was not. However, controlling for sex strengthened the relationship between SMI and MetS, and the 
degree of statistical significance increased. 
Table 2 about here 
We next carried out logistic analysis of the effect of SMI on the prevalence of MetS (Table 3), controlling for 
sociodemographic variables significantly related in univariate analysis. SMI, age, smoking status and a family history of 
CVD remained significantly associated with MetS, while family situation and gender did not. 
Table 3 about here 
We then tested our specific hypotheses relating to potential mediators of the relationship between SMI and MetS, that 
is, a family history of cardiovascular disease, antipsychotic medication dose and smoking status. These analyses each 
included age as an independent variable because of its established effect on MetS. The results are presented in table 4. 
As we have seen, a family history of CVD was strongly associated with the metabolic syndrome. However, the 
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proportion of the effect of SMI on MetS that was mediated by family history was minuscule: virtually all the effect was 
therefore direct. Thus, in our data, a family history of CVD cannot explain the excess of MetS in people with SMI. 
What about the effect of medication dosage? It should be noted that in the SMI group, 115 of 119 (97%) were taking 
antipsychotics (atypical in 110). The median chlorpromazine dose was moderate, at 242 mg daily (interquartile range of 
150–483 mg). The indirect component of the SMI-MetS link due to dose of medication appears at first sight to be 
appreciable, representing about 32% of the total effect. However, the direction of effect was the reverse of what we 
hypothesised – it seems as if the link between SMI and MetS was attenuated by increasing doses of antipsychotic 
medication. It should be noted that the contribution of dosage to the model was non-significant (p=0.16).  
Finally we analysed the effect of smoking status. In this instance about 10% of the overall link between SMI and MetS 
was indirect, through smoking. However, this effect was, once more, non-significant (p=0.19): in our sample, smoking 
is also unable to account for the relationship between SMI and MetS. 
Table 4 about here 
DISCUSSION 
We compared an epidemiologically representative random sample of inpatients with SMI with an appropriate 
comparison group. DSM-IV research diagnoses for SMI were based on formal diagnostic interviews. The role of 
possible confounders was addressed at the stage of design for the index and the comparison groups (through random 
sampling) and at the stage of analysis for the whole sample (by adjusting for a selected set of variables). 
Main findings 
The prevalence of 26% for MetS rates in our SMI group is consistent with earlier studies from other countries belonging 
to the low cardiovascular risk region of southern Europe [29]. Similar rates have been reported in outpatients samples 
from Spain [17], although a prevalence of ATP III MetS of 34.2% in a Turkish cohort was higher (27.7% for men, 
39.3% for women) [16]. Values of 32.5% were reported from the United States in a recent meta-analysis, and more 
significantly, our results are lower than any so far reported from inpatient samples, as for this subgroup the pooled rate 
of MetS was 30.4% [8]. The only comparable rates (24%) come from a Spanish cross-sectional study in patients 
diagnosed with schizophrenia admitted to short-stay hospitalisation units [15].  
The age-adjusted general population prevalence of MetS is similar in the USA [30] and in Italy [26]. The single largest 
US study so far [7] used a large general population comparison sample [30], and reported an unadjusted OR of suffering 
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from Mets, given SMI, of 1.94 (95% CIs= 1.52–2.47). The analogous unadjusted OR from our data was 1.85 (95% CIs= 
0.98–3.50). Thus, given SMI, the relative odds of having MetS seem roughly equivalent in the USA and in Italy.  
However, after adjustment for age and sex, people suffering from SMI were three times more likely to suffer from MetS 
than our chosen controls. Thus, in this low prevalence population with traditionally healthy dietary habits, SMI does 
have a prominent effect in increasing the likelihood of MetS. It is also clear, from our analysis as a whole, that a family 
history of CVD and smoking are MetS risk factors in both the SMI case group and our control sample. A history of 
cardiovascular disease increased fivefold the likelihood of suffering from MetS: this is consistent with data from the 
general population [5]. The corresponding odds ratio for smoking was around 2.5, somewhat greater than in other 
reports from the Italian general population (OR=1.34) [31].  
We investigated whether these factors, along with the dose of antipsychotic medication, could account for the excess of 
MetS in the SMI group, by using formal tests of mediation. Smoking can be taken here as an example of adverse health 
behaviour, and we used a family history of CVD as a partial proxy for genetic overlap between MetS and SMI. In the 
event, none of these factors could explain the higher rates of MetS in the SMI group.  
It has been argued that people with SMI have a particular susceptibility to metabolic abnormalities and there may be 
genetic risk factors common to diabetes and schizophrenia [32]. However, over 100 genes are associated with 
schizophrenia, the associations are very weak (OR <1.15), and between them they explain only 5% of the variance [33]. 
In order to account for much of the SMI-MetS link, a large number of these genes would also have to be associated with 
MetS. This seems unlikely, to say the least, and so it is not surprising that family history of CVD did not mediate the 
SMI-MetS link.  
Our mediation analysis yielded a central value implying that 10% of the link between SMI and MetS might be mediated 
by smoking. However this effect was not statistically significant. A role for smoking does remain possible because we 
were unable to collect detailed information about smoking levels, and its association with MetS is likely to be dose-
dependent [34]. Poor health behaviours as a whole may yet lie at the heart of the high prevalence of MetS in people 
with SMI.  
While age and familial predisposition are non-modifiable risk factors, it has been strongly argued that poor diet and 
poor health habits are proper targets for intervention. People with SMI are relatively ignorant of CVD risk factors and 
interventions and appear to give less priority to their physical health needs [12]. Their motivation to change their health 
behaviour may be affected by disbelief, both that such change can reduce risks and that they have the ability to change, 
though their motivation for weight loss may be just as strong as in the general population [35]. Modifying and 
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implementing programmes to change the health beliefs and behaviours of the severely mentally ill population clearly 
remains a challenge.  
In our age-controlled mediation analysis, we were unable to find any association between the dose of antipsychotic 
medication and the likelihood of suffering from MetS. This is surprising: if antipsychotic medication tends to induce 
MetS in the people who take it, it should account for some of the excess of MetS in people with SMI, and there ought to 
be a dose effect. The absence of mediation by antipsychotic dose may suggest that, at the population level at least, such 
drugs do not contribute much to the excess, or perhaps that much of the medication effect is already apparent at low 
dosage. We quantified the use of antipsychotic agents in the previous six months, but MetS may require a longer period 
to become apparent, and thus reflect cumulative dosage levels [36]. Equally, we could not assess intermittent 
antipsychotic usage, often related to poor compliance. Finally physicians may seek preferentially to lower medication 
dosage in people with increasing BMI. People with SMI may have a propensity to develop metabolic abnormalities 
regardless of antipsychotic medication [37], but our failure to find a dose effect must be set against evidence that 
adverse cardio-metabolic risks appear within weeks of commencing anti-psychotics, particularly weight gain, glucose 
dysregulation and hypercholesterolemia [38], not to mention sudden cardiac death [39]. Thus we should certainly opt 
for the least metabolically impairing antipsychotics.  
Limitations 
The setting, the manner of delivery of interventions and the exclusion criteria are relatively similar to those found 
elsewhere, allowing reasonable generalizability to similar populations in Western countries. Nevertheless, as MetS was 
assessed in treated populations, our findings may differ from those in people out of contact with services. Although the 
procedure for identifying SMI was based on the use of a standardised instrument (the SCID-I), the reliability of ratings 
was not formally established during the study, and additional clinical characteristics could be assessed in order to 
control their confounding role. Furthermore, sample size calculations were based on a 40 % event rate in people with 
SMI according to the International literature. However this is much higher than that observed in our local sample 
(26%), possibly affecting power and bringing risk of random error. In addition, we could study only smoking but the 
role of other adverse health behaviours (e.g., poor diet and lack of exercise) deserves further research in people with 
SMI. While attempts were made to ensure comparable recruitment procedures, acute-phase treatment might have 
exacerbated the metabolic disturbances. Furthermore, although people from the maxillofacial surgery unit admitted for 
planned, routine (non-emergency) surgical treatment have been chosen because they are likely to be free from any 
medical chronic condition, they cannot be perfect proxies for the general population. Cross-sectional studies constrain 
causal inference, but the fact that there was a strong association of MetS with smoking but not with the dose of 
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antipsychotic medication makes a differential causal effect plausible, particularly as in both cases there is a putative 
mechanism.  
CONCLUSION 
Despite the comparatively low prevalence of MetS in this study, it still has significant public health implications for the 
marginalised group of people with SMI, whose disadvantages often include further comorbid issues such as substance 
dependence and cognitive impairment [40, 41] and a wide range of severe physical illnesses [10]. The Mediterranean 
countries have traditionally shown lower cardiovascular mortality rates than other developed countries, so there is a 
particular need for monitoring, diagnosing, treating, and educating people with SMI about the associated metabolic 
abnormalities. In particular, health promotion for people with SMI should aim to raise awareness of modifiable health 
behaviours such as smoking, overeating, consumption of relatively unhealthy foods and inactivity [42, 43]. Future 
research should include not only the follow-up of samples in different regions in order to assess the relative contribution 
of life style and health behaviours to MetS, but also appropriate guidelines [12] about effective health promotion 
interventions targeting physical activity, eating habits and smoking cessation. 
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Table 1 Socio-demographic characteristics, metabolic syndrome and severe mental illness (SMI) 
Variable With SMI (n=119) Without SMI (n=119) P 
Age: Mean (SD), yrs 47.2 (14.8) 49.4 (19.7)    0.32 
Sex: Male 51 (42.9%) 65 (54.6%)   0.069 
Education: ≥High school 58 (48.7%) 56 (47.1%)    0.80 
Married/cohabiting: 28 (23.5%) 64 (54.7%) <0.001 
Employed: 58 (48.7%) 104 (87.4%) <0.001 
ATP III Metabolic Syndrome 
Males 
Females 
31 (26.1%) 
12 (23.5%) 
19 (27.9%) 
19 (15.9%) 
13 (20%) 
    6 (11.1%) 
  0.056 
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Table 2 Severe mental illness, sex and the metabolic syndrome: logistic regression 
Variables Odds Ratio 95% CIs  P 
SMI 1.85 0.98-3.51   0.058 
SMI (males) 1.23 0.51-2.99 0.65  
SMI (females) 3.10 1.14-8.44   0.027 
SMI 
Sex (reference female) 
SMI*sex 
Age 
4.53 
3.07 
0.41 
1.06 
1.54-13.36 
1.00-9.43 
0.10-1.69 
1.03-1.08 
  0.006 
0.05 
  0.215 
    0.0001 
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Table 3 Variables associated with ATP III Metabolic Syndrome: logistic regression 
Variables Odds Ratio 95% CI P 
SMI 3.42 1.49 to 7.86 0.004 
Age 1.03 1.01 to 1.07 0.005 
Sex 0.77 0.36 to 1.63 0.499 
Ever smoked 2.48 1.09 to 5.61 0.029 
Family situationa 2.17  0.96 to 4.88 0.062 
Family history of cardiovascular disease 5.10 1.88 to 13.83 0.001 
aReference category: living alone 
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Table 4 Tests of mediation between SMI and MetS: Family history of cardiovascular disease (FH CVD),  
Antipsychotic medication and Smoking status 
Term Coefficient Standard error t P 
FH CVD .008 .053 0.15 0.89 
SMI .12 .051 2.29 0.023 
Age .007 .001 4.51 0.0001 
Sobel-Goodman test of mediation   Z  
Indirect effect -.0001 .0008 -0.12 0.90 
Direct effect .116 .051 2.29 0.022 
Total effect .116 .051 2.29 0.022 
Term Coefficient Standard error t P 
CPZ equivalent dose -.0002 .0001 -1.44 0.15 
SMI .165 .058 2.07 0.04 
Age .007 .001 4.60 0.0001 
Sobel-Goodman test of mediation   Z  
Indirect effect -.040 .028 -1.42 0.16 
Direct effect .165 .058 2.84 0.004 
Total effect .125 .051 2.45 0.014 
Term Coefficient Standard error t P 
Smoker vs. non-smoker .098 .051 1.91 0.06 
SMI .105 .051 2.07 0.04 
Age .007 .001 4.76 0.0001 
Sobel-Goodman test of mediation   Z  
Indirect effect .011 .009 1.31 0.19 
Direct effect .105 .051 2.07 0.04 
Total effect .116 .051 2.29 0.022 
 
 
 
 
 
